SCHEMBL6157256

SCHEMBL6157256

Oc1[nH][c]nc1-c1ccccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.45
LMNA P02545 3/20 0.45
CCR1 P32246 2/20 0.45
CCR5 P51681 2/20 0.45
CCR8 P51685 2/20 0.45
CYP1A2 P05177 1/20 0.45
POLB P06746 1/20 0.45
METAP1 P53582 1/20 0.45
BLM P54132 1/20 0.45
HIF1A Q16665 1/20 0.45
DOHH Q9BU89 1/20 0.45
P4HTM Q9NXG6 1/20 0.45
LRRK2 Q5S007 1/20 0.41
NPC1 O15118 6/20 0.40
RAB9A P51151 4/20 0.40
TP53 P04637 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
ALOX15 P16050 2/20 0.39
HTT P42858 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10326320 0.80 KDM4E (0.46) KDM4ELMNACCR1CCR5CCR8
SCHEMBL1900332 0.79 KDM4E (0.47) KDM4ELMNACCR1CCR5CCR8
SCHEMBL11166709 0.76 NPY5R (0.45) KDM4ELMNACCR1CCR5CCR8
SCHEMBL4775698 0.72 IDO1 (0.41) KDM4ELMNACCR1CCR5CCR8
SCHEMBL18154008 0.69 KDM4E (0.46) KDM4ELMNACCR1CCR5CCR8
SCHEMBL8894024 0.67 KDM4E (0.54) KDM4ELMNACCR1CCR5CCR8
SCHEMBL2573127 0.67 KDM4E (0.54) KDM4ELMNACCR1CCR5CCR8
SCHEMBL323086 0.67 KDM4E (0.68) KDM4ELMNACCR1CCR5CCR8
SCHEMBL176039 0.67 KDM4E (0.68) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL27651116 0.66 KDM4E (0.88) KDM4ELMNACCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0832071-B1 1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDE IV AND CYTOKININ INHIBITING ACTIVITY JANSSEN PHARMACEUTICA NV (BE) 2005-09-28 EP disclosed
CN-1103760-C 1, 3-dihydro-2H-imidazol-2-one derivatives having PDEIV and cytokine inhibitory activity JANSSEN PHARMACEUTICA NV (BE) 2003-03-26 CN disclosed
US-20020068830-A1 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES FREYNE EDDY JEAN EDGARD (BE) 2002-06-06 US disclosed
EP-0819122-B1 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY JANSSEN PHARMACEUTICA NV (BE) 2002-03-06 EP disclosed
US-6180355-B1 Method for diagnosing and treating chronic pelvic pain syndrome UNIVERSITY OF MARYLAND, BALTIMORE 2001-01-30 US disclosed
US-5869515-A TREATING ASTHMATIC OR ATOPIC DISEASES JANSSEN PHARMACEUTICA N.V. (BE) 1999-02-09 US disclosed
CN-1181073-A 1, 3 -dihydro -2H -imidazol -2 -one derivatives having PDEIV and cytokinin inhibiting activity JANSSEN PHARMACEUTICA NV (BE) 1998-05-06 CN disclosed
EP-0832071-A1 1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDE IV AND CYTOKININ INHIBITING ACTIVITY JANSSEN PHARMACEUTICA N.V. (BE) 1998-04-01 EP disclosed
EP-0819122-A1 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY JANSSEN PHARMACEUTICA N.V. (BE) 1998-01-21 EP disclosed
WO-1996031487-A1 1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDE IV AND CYTOKININ INHIBITING ACTIVITY JANSSEN PHARMACEUTICA N.V. (BE) 1996-10-10 WO disclosed
WO-1996031485-A1 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY JANSSEN PHARMACEUTICA N.V. (BE) 1996-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068830-A1 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HRH2, CBR1, HRH1 KDM4E 2378/4885LMNA 3113/4885CCR1 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.